March 31, 2025 06:30 AM EDTUpdated 09:01 AM

BiomX’s phage therapy succeeds in Phase 2 diabetic bone infection study

Ayisha Sharma

News Reporter

BiomX’s antibacterial virus candidate has reduced the size of foot ulcers in patients with diabetic bone infection enrolled in a mid-stage trial. The finding could …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BiomX’s phage therapy succeeds in Phase 2 diabetic bone infection study

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Sanofi continues its bet on R&D by poaching GSK’s head of development

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Bio­mX’s phage ther­a­py suc­ceeds in Phase 2 di­a­bet­ic bone in­fec­tion study

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Fir­ings sweep across FDA as for­mer lead­ers lament the gut­ting of drug agency

RFK Jr. has long crit­i­cized drug ads. He just slashed the FDA of­fice that reg­u­lates them

‘It’ll be a chal­lenge’: BIO chief Crow­ley ad­dress­es seis­mic FDA over­haul

Sanofi con­tin­ues its bet on R&D by poach­ing GSK’s head of de­vel­op­ment

Big am­bi­tions at Mer­ck and As­traZeneca — along with a few gi­ant pit­falls — re­shape top ranks of the R&D 15

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

BiomX’s phage therapy succeeds in Phase 2 diabetic bone infection study

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Sanofi continues its bet on R&D by poaching GSK’s head of development

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO